Full Press Release Details
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight.
ALT
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Key Takeaway: Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Price reaction · baseline $2.43 (2023-09-11 close) · hit after-hours · clean, no other ALT news in the window
day 0 close
+7.4%
day 1
+9.9%
day 3 · peak
+20.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight